Agilent Technologies, Inc. (NYSE:A) Shares Sold by Deutsche Bank AG

Key Points

• Deutsche Bank AG reduced its holdings in Agilent Technologies by 8.7%, selling 386,152 shares, and now owns approximately 1.42% of the company valued at $473.8 million.
• Agilent Technologies reported a quarterly earnings increase with an EPS of $1.31, surpassing estimates, and had a revenue of $1.67 billion, up 6.0% from the previous year.
• The company declared a quarterly dividend of $0.248 per share, providing an annualized yield of 0.9%, with a dividend payout ratio of 24.44%.

Deutsche Bank AG reduced its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 8.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,050,548 shares of the medical research company's stock after selling 386,152 shares during the quarter. Deutsche Bank AG owned 1.42% of Agilent Technologies worth $473,833,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC increased its position in Agilent Technologies by 15,648.1% during the first quarter. GAMMA Investing LLC now owns 627,247 shares of the medical research company's stock valued at $73,375,000 after acquiring an additional 623,264 shares during the last quarter. Two Sigma Investments LP increased its position in Agilent Technologies by 345.9% during the fourth quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company's stock valued at $103,428,000 after acquiring an additional 597,249 shares during the last quarter. Iron Triangle Partners LP purchased a new stake in Agilent Technologies during the fourth quarter valued at $80,110,000. Marshall Wace LLP increased its position in Agilent Technologies by 280.3% in the fourth quarter. Marshall Wace LLP now owns 806,895 shares of the medical research company's stock worth $108,398,000 after buying an additional 594,744 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in Agilent Technologies by 141.5% in the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company's stock worth $109,481,000 after buying an additional 548,344 shares in the last quarter.

Analyst Upgrades and Downgrades

A has been the subject of a number of research reports. UBS Group dropped their price target on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a research note on Thursday, May 29th. JPMorgan Chase & Co. lowered their price objective on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research note on Thursday, May 29th. Barclays raised their price objective on Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a research note on Tuesday, June 24th. Evercore ISI raised their price objective on Agilent Technologies from $125.00 to $130.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Finally, Leerink Partners raised their price objective on Agilent Technologies to $135.00 and gave the company a "buy" rating in a research note on Friday, May 30th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $139.77.

Agilent Technologies Trading Up 0.6%

NYSE:A traded up $0.71 during trading hours on Friday, reaching $114.69. 1,129,747 shares of the stock were exchanged, compared to its average volume of 1,744,167. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average of $117.39 and a two-hundred day moving average of $119.66. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $153.84. The company has a market capitalization of $32.58 billion, a price-to-earnings ratio of 28.32, a PEG ratio of 3.46 and a beta of 1.22.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.05. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.63 billion. During the same quarter in the prior year, the business earned $1.22 EPS. Agilent Technologies's revenue was up 6.0% on a year-over-year basis. On average, equities analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 23rd. Investors of record on Tuesday, July 1st were issued a dividend of $0.248 per share. The ex-dividend date of this dividend was Tuesday, July 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.9%. Agilent Technologies's dividend payout ratio (DPR) is currently 24.44%.

Insider Activity

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares in the company, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.